# Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
Canonical URL: https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-present-new-long-term-and-safety-data-across-gene-therapy-and-exon-skipping-programs-at-2026-muscular-dystrophy-association-clinical-and-scientific-congress
Ticker: SRPT
Company: Sarepta Therapeutics
Source: Sarepta Therapeutics
Published: 2026-02-26 13:30 EST
Original Source URL: https://investorrelations.sarepta.com
## Summary

Several abstracts, including a late-breaking podium presentation and posters, bring forward accumulating long-term efficacy, safety and caregiver-reported insights that deepen understanding of dystrophin restoration and its impact in Duchenne CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.

## Article Body
Several abstracts, including a late-breaking podium presentation and posters, bring forward accumulating long-term efficacy, safety and caregiver-reported insights that deepen understanding of dystrophin restoration and its impact in Duchenne CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.
## Recent Company News
- 2026-06-01 20:30 EST — [Sarepta Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Sarepta Therapeutics
- 2026-05-13 20:30 EST — [Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference) — Source: Sarepta Therapeutics
- 2026-05-06 20:05 EST — [Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2026-financial-results-and-recent-corporate-developments) — Source: Sarepta Therapeutics
- 2026-04-22 12:30 EST — [Sarepta Therapeutics to Announce First Quarter 2026 Financial Results](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-announce-first-quarter-2026-financial-results) — Source: Sarepta Therapeutics
- 2026-03-31 20:05 EST — [Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Sarepta Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)